3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling

Journal of Molecular Endocrinology

Volumn 54, Issue 3, 2015, Pages 205-216

  Dinter, Juliane ^a   Mühlhaus, Jessica ^a   Jacobi, Simon Friedrich ^a,b   Wienchol, Carolin Leonie ^a   Cöster, Maxi ^c   Meister, Jaroslawna ^c   Hoefig, Carolin Stephanie ^b   Müller, Anne ^a   Köhrle, Josef ^a   Grüters, Annette ^a   Krude, Heiko ^a   Mittag, Jens ^b   Schöneberg, Torsten ^c   Kleinau, Gunnar ^a   Biebermann, Heike ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

3 T1AM; Adrenergic receptor; G protein coupled receptor; Thyronamine

Indexed keywords

3 IODOTHYRONAMINE; ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; DIMETHYL SULFOXIDE; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GLYCOGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORADRENALIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PYRUVATE KINASE; RNA; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG; 3-IODOTHYRONAMINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; THYRONINE DERIVATIVE; TRACE AMINE-ASSOCIATED RECEPTOR 1;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL STIMULATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; EMBRYO; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; GLYCOGEN LIVER LEVEL; GLYCOLYSIS; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; 129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; GENE EXPRESSION; GENETICS; METABOLISM; PRECLINICAL STUDY;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GLUCOSE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEK293 CELLS; HUMANS; ISLETS OF LANGERHANS; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; THYRONINES;

EID: 84949783020     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-15-0003     Document Type: Article

References (42)

1. Barnes PJ 2006 Receptor heterodimerization: a new level of cross-talk. Journal of Clinical Investigation 116 1210-1212. (doi:10. 1172/JCI28535)
2. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S et al. 2001 Trace amines: identification of a family of mammalian G protein-coupled receptors. PNAS 98 8966-8971. (doi:10. 1073/pnas. 151105198)
3. Braulke LJ, Klingenspor M, DeBarber A, Tobias SC, Grandy DK, Scanlan TS & Heldmaier G 2008 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation. Journal of Comparative Physiology. B, Biochemical, Systemic, and Environmental Physiology 178 167-177. (doi:10. 1007/s00360-007-0208-x)
4. Bylund DB & Ray-Prenger C 1989 Alphα-2A and α-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. Journal of Pharmacology and Experimental Therapeutics 251 640-644.
5. Covic L, Gresser AL, Talavera J, Swift S & Kuliopulos A 2002 Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. PNAS 99 643-648. (doi:10. 1073/pnas. 022460899)
6. Dhillo WS, Bewick GA, White NE, Gardiner JV, Thompson EL, Bataveljic A, Murphy KG, Roy D, Patel NA, Scutt JN et al. 2009 The thyroid hormone derivative 3-iodothyronamine increases food intake in rodents. Diabetes, Obesity & Metabolism 11 251-260. (doi:10. 1111/j. 1463-1326. 2008. 00935. x)
7. Eishingdrelo H & Kongsamut S 2013Minireview: Targeting GPCR activated ERK pathways for drug discovery. Current Chemical Genomics and Translational Medicine 7 9-15. (doi:10. 2174/2213988501307010009)
8. Eizirik DL, SammethM, Bouckenooghe T, Bottu G, Sisino G, Igoillo-EsteveM, Ortis F, Santin I, Colli ML, Barthson J et al. 2012 The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genetics 8 e1002552. (doi:10. 1371/journal. pgen. 1002552)
9. Fagerholm V, Gronroos T, Marjamaki P, Viljanen T, Scheinin M & Haaparanta M 2004 Altered glucose homeostasis in α2A-adrenoceptor knockout mice. European Journal of Pharmacology 505 243-252. (doi:10. 1016/j. ejphar. 2004. 10. 023)
10. Galli E, Marchini M, Saba A, Berti S, Tonacchera M, Vitti P, Scanlan TS, Iervasi G & Zucchi R 2012 Detection of 3-iodothyronamine in human patients: a preliminary study. Journal of Clinical Endocrinology and Metabolism 97 E69-E74. (doi:10. 1210/jc. 2011-1115)
11. Haviland JA, Reiland H, Butz DE, Tonelli M, Porter WP, Zucchi R, Scanlan TS, Chiellini G & Assadi-Porter FM 2013 NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment. Obesity 21 2538-2544. (doi:10. 1002/oby. 20391)
12. Hettinger BD, Marks D & Scanlan TS 2010 3-Iodothyronamine (T1AM) causes weight loss in mice via reduction in food consumption. In 14th International Thyroid Congress: OC-141. Paris, France.
13. Hoefig CS, Kohrle J, Brabant G, Dixit K, Yap B, Strasburger CJ & Wu Z 2011 Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Journal of Clinical Endocrinology and Metabolism 96 1864-1872. (doi:10. 1210/jc. 2010-2680)
14. Huang ES 2003 Construction of a sequence motif characteristic of aminergic G protein-coupled receptors. Protein Science 12 1360-1367. (doi:10. 1110/ps. 0305603)
15. Kleinau G, Pratzka J, Nurnberg D, Gruters A, Fuhrer-Sakel D, Krude H, Kohrle J, Schoneberg T & Biebermann H 2011 Differential modulation of β-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS ONE 6 e27073. (doi:10. 1371/journal. pone. 0027073)
16. Kratochwil NA, Malherbe P, Lindemann L, Ebeling M, Hoener MC, Muhlemann A, Porter RH, Stahl M & Gerber PR 2005 An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application. Journal of Chemical Information and Modeling 45 1324-1336. (doi:10. 1021/ci050221u)
17. Lambert NA 2010 GPCR dimers fall apart. Science Signaling 3 pe12. (doi:10. 1126/scisignal. 3115pe12)
18. Manni ME, De Siena G, Saba A, MarchiniM, Dicembrini I, Bigagli E, Cinci L, Lodovici M, Chiellini G, Zucchi R et al. 2012 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice. British Journal of Pharmacology 166 650-658. (doi:10. 1111/j. 1476-5381. 2011. 01823. x)
19. McGraw DW, Mihlbachler KA, Schwarb MR, Rahman FF, Small KM, Almoosa KF & Liggett SB 2006 Airway smooth muscle prostaglandin-EP1 receptors directly modulate β2-adrenergic receptors within a unique heterodimeric complex. Journal of Clinical Investigation 116 1400-1409. (doi:10. 1172/JCI25840)
20. Meister J, Le Duc D, Ricken A, Burkhardt R, Thiery J, Pfannkuche H, Polte T, Grosse J, Schoneberg T & Schulz A 2014 The G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice. Journal of Biological Chemistry 289 23353-23366. (doi:10. 1074/jbc. M114. 580803)
21. Panas HN, Lynch LJ, Vallender EJ, Xie Z, Chen GL, Lynn SK, Scanlan TS & Miller GM 2010 Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice. Journal of Neuroscience Research 88 1962-1969. (doi:10. 1002/jnr. 22367)
22. Piechowski CL, Rediger A, Lagemann C, Muhlhaus J, Muller A, Pratzka J, Tarnow P, Gruters A, Krude H, Kleinau G et al. 2013 Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. Journal of Molecular Endocrinology 51 109-118. (doi:10. 1530/ JME-13-0061)
23. Piehl S, Hoefig CS, Scanlan TS & Kohrle J 2011 Thyronamines-past, present, and future. Endocrine Reviews 32 64-80. (doi:10. 1210/ er. 2009-0040)
24. RedigerA, Piechowski CL, Yi CX, TarnowP, Strotmann R, Gruters A, KrudeH, Schoneberg T, Tschop MH, Kleinau G et al. 2011 Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. Journal of Biological Chemistry 286 39623-39631. (doi:10. 1074/jbc. M111. 287607)
25. i in vivo identifies GPCR regulators of insulin secretion. Journal of Clinical Investigation 117 4034-4043. (doi:10. 1172/JCI32994)
26. Roberts A, Pimentel H, Trapnell C & Pachter L 2011 Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics 27 2325-2329. (doi:10. 1093/bioinformatics/btr355)
27. Roeder T 2005 Tyramine and octopamine: ruling behavior and metabolism. Annual Review of Entomology 50 447-477. (doi:10. 1146/ annurev. ento. 50. 071803. 130404)
28. Rosengren AH, JokubkaR, TojjarD, GranhallC, HanssonO, LiDQ, NagarajV, Reinbothe TM, Tuncel J, Eliasson L et al. 2010 Overexpression of α2A-adrenergic receptors contributes to type 2 diabetes. Science 327 217-220. (doi:10. 1126/science. 1176827)
29. Rozenfeld R & Devi LA 2007 Receptor heterodimerization leads to a switch in signaling: β-arrestin2-mediated ERK activation by μ-δ opioid receptor heterodimers. FASEB Journal 21 2455-2465. (doi:10. 1096/ fj. 06-7793com)
30. Rozenfeld R & Devi LA 2011 Exploring a role for heteromerization in GPCR signalling specificity. Biochemical Journal 433 11-18. (doi:10. 1042/ BJ20100458)
31. Saba A, Chiellini G, Frascarelli S, Marchini M, Ghelardoni S, Raffaelli A, Tonacchera M, Vitti P, Scanlan TS & Zucchi R 2010 Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology 151 5063-5073. (doi:10. 1210/en. 2010-0491)
32. Scanlan TS 2009 Minireview: 3-Iodothyronamine (T1AM): a new player on the thyroid endocrine team? Endocrinology 150 1108-1111. (doi:10. 1210/en. 2008-1596)
33. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S et al. 2004 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nature Medicine 10 638-642. (doi:10. 1038/nm1051)
34. Schoneberg T, Yun J, Wenkert D&Wess J 1996 Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. EMBO Journal 15 1283-1291.
35. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O & Lefkowitz RJ 2006 Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. Journal of Biological Chemistry 281 1261-1273. (doi:10. 1074/ jbc. M506576200)
36. SjogrenM, AlkemadeA, Mittag J, NordstromK, KatzA, RozellB, WesterbladH, Arner A & Vennstrom B 2007 Hypermetabolism in mice caused by the central action of an unliganded thyroid hormone receptor α1. EMBO Journal 26 4535-4545. (doi:10. 1038/sj. emboj. 7601882)
37. Tang Y, Axelsson AS, Spegel P, Andersson LE, Mulder H, Groop LC, Renstrom E & Rosengren AH 2014 Genotype-based treatment of type 2 diabetes with an α2A-adrenergic receptor antagonist. Science Translational Medicine 6 257ra139. (doi:10. 1126/scitranslmed. 3009934)
38. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL & Pachter L 2012 Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature Protocols 7 562-578. (doi:10. 1038/nprot. 2012. 016)
39. 3) is a survival factor for pancreatic β-cells undergoing apoptosis. Journal of Cellular Physiology 206 309-321. (doi:10. 1002/jcp. 20460)
40. Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z & Lohse MJ 2008 Conformational cross-talk between α2A-adrenergic and μ-opioid receptors controls cell signaling. Nature Chemical Biology 4 126-131. (doi:10. 1038/nchembio. 64)
41. Vujovic M, Nordstrom K, Gauthier K, Flamant F, Visser TJ, Vennstrom B & Mittag J 2009 Interference of a mutant thyroid hormone receptor α1 with hepatic glucose metabolism. Endocrinology 150 2940-2947. (doi:10. 1210/en. 2008-1085)
42. Zucchi R, Accorroni A & Chiellini G 2014 Update on 3-iodothyronamine and its neurological andmetabolic actions. Frontiers in Physiology 5 402. (doi:10. 3389/fphys. 2014. 00402)